Objective To explore the O6-methylguanine DNA methyltransferase(MGMT)promoter methylation on the quality of postoperative prognosis in patients with new wild-type glioblastoma(GBM).Methods The clinical data of 41 patients with wild-type GBM isocitrate dehydrogenase(IDH)newly diagnosed in Department of Neurosurgery,the First Affiliated Hospital of Xinjiang Medical University from 2019 to 2022 were analyzed retrospectively.MGMT promoter methylation status was assessed in GBM patients by pyrosequencing,while simultaneously analyzed for correlation with patient outcome quality.Results The incidence of MGMT promoter methylation in all patients was 43％.Patients with MGMT methylated promoters had significantly higher median survival than unmethylated patients(P＜0.05),and overall survival was significantly longer than unmethylated patients(P＜0.05).Conclusion MGMT promoter methylation can prolong the survival after postoperative chemoradiotherapy in patients with IDH wild-type GBM,but no linear relationship is observed,which suggesting that the effect of MGMT promoter methylation on prognosis may be different.
万方数据
